EA200600866A1 - Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний - Google Patents

Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний

Info

Publication number
EA200600866A1
EA200600866A1 EA200600866A EA200600866A EA200600866A1 EA 200600866 A1 EA200600866 A1 EA 200600866A1 EA 200600866 A EA200600866 A EA 200600866A EA 200600866 A EA200600866 A EA 200600866A EA 200600866 A1 EA200600866 A1 EA 200600866A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
neurodegenerative diseases
application
hydroxymic acid
halides
Prior art date
Application number
EA200600866A
Other languages
English (en)
Other versions
EA011301B1 (ru
Inventor
Линда Гринсмит
Джеффри Бернсток
Рудольф Урбанич
Original Assignee
СиУайТиАрЭкс КОРПОРЕЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиУайТиАрЭкс КОРПОРЕЙШН filed Critical СиУайТиАрЭкс КОРПОРЕЙШН
Publication of EA200600866A1 publication Critical patent/EA200600866A1/ru
Publication of EA011301B1 publication Critical patent/EA011301B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к применению химического вещества, выбранного из группы, состоящей из N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксимидоил хлорида, оптически активных энантиомеров и смеси этих энантиомеров, и фармацевтически пригодных солей рацемических и оптически активных соединений для приготовления фармацевтической композиции для лечения или предупреждения нейродегенеративных заболеваний.
EA200600866A 2003-10-30 2004-10-25 Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний EA011301B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303584A HUP0303584A3 (en) 2003-10-30 2003-10-30 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
PCT/HU2004/000098 WO2005041965A1 (en) 2003-10-30 2004-10-25 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
EA200600866A1 true EA200600866A1 (ru) 2006-10-27
EA011301B1 EA011301B1 (ru) 2009-02-27

Family

ID=89981738

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600866A EA011301B1 (ru) 2003-10-30 2004-10-25 Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний

Country Status (27)

Country Link
US (3) US20080039497A1 (ru)
EP (2) EP2020233A3 (ru)
JP (1) JP5077997B2 (ru)
KR (1) KR20060103323A (ru)
CN (1) CN1901913A (ru)
AT (1) ATE409038T1 (ru)
AU (1) AU2004285343B2 (ru)
BR (1) BRPI0415625A (ru)
CA (1) CA2544332C (ru)
CY (1) CY1110450T1 (ru)
CZ (1) CZ2006347A3 (ru)
DE (1) DE602004016770D1 (ru)
DK (1) DK1696922T3 (ru)
EA (1) EA011301B1 (ru)
ES (1) ES2314458T3 (ru)
HK (1) HK1097438A1 (ru)
HR (1) HRP20080660T3 (ru)
HU (1) HUP0303584A3 (ru)
IL (1) IL175334A (ru)
NO (1) NO20062401L (ru)
NZ (1) NZ547216A (ru)
PL (1) PL1696922T3 (ru)
PT (1) PT1696922E (ru)
SI (1) SI1696922T1 (ru)
UA (1) UA86782C2 (ru)
WO (1) WO2005041965A1 (ru)
ZA (1) ZA200604376B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384936B2 (en) 2002-01-11 2008-06-10 Cytrx Corporation Carboxamidine derivatives and their use in the treatment of vascular diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
ES2963910T3 (es) 2008-06-26 2024-04-03 Zevra Denmark As Uso de Hsp70 como regulador de la actividad enzimática
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
EP2646044B1 (en) 2010-11-30 2019-08-28 Orphazyme A/S Methods for increasing intracellular activity of hsp70
HUP1100534A2 (en) * 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
CN103804309B (zh) * 2012-11-09 2019-08-02 广州喜鹊医药有限公司 一种氯肟类化合物及其制备方法和在制药中的应用
AU2015317447B2 (en) * 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
HUE052158T2 (hu) * 2016-04-29 2021-04-28 Orphazyme As Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez
BR112019024667A2 (pt) 2017-05-24 2020-06-16 Orphazyme A/S Uso de um agente bioativo, e, de uma composição
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
JP2024500632A (ja) 2020-11-19 2024-01-10 ゼブラ デンマーク エー／エス アリモクロモルクエン酸塩及びその中間体の調製プロセス

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
DE2651083A1 (de) 1976-11-09 1978-05-18 Hoechst Ag Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
NZ285151A (en) 1994-05-06 1998-09-24 Biorex Kutato Fejlesztoe Kft Hydroximic acid derivatives
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
UA64716C2 (en) 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
UA65635C2 (ru) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСЫЧЕННЫЕ ПРОИЗВОДНЫЕ ГИДРОКСИМОВОЙ КИСЛОТЫ, ИМЕЮЩИЕ СВОЙСТВА ИНГИБИТОРОВ NAD<sup>+-ADP-РИБОЗИЛТРАНСФЕРАЗЫ
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
ITMI20012573A1 (it) 2001-12-06 2003-06-06 D B P Dev Biotechonologica L P Gli acilsalicilati:una nuova classe di induttori di risposta heat shock

Also Published As

Publication number Publication date
EP1696922A1 (en) 2006-09-06
AU2004285343A1 (en) 2005-05-12
US20080039497A1 (en) 2008-02-14
JP5077997B2 (ja) 2012-11-21
SI1696922T1 (sl) 2008-12-31
HUP0303584A3 (en) 2009-12-28
PT1696922E (pt) 2008-10-17
CA2544332A1 (en) 2005-05-12
JP2007509920A (ja) 2007-04-19
CN1901913A (zh) 2007-01-24
NZ547216A (en) 2009-03-31
CZ2006347A3 (cs) 2006-10-11
EP1696922B1 (en) 2008-09-24
IL175334A (en) 2010-12-30
BRPI0415625A (pt) 2006-12-12
NO20062401L (no) 2006-07-27
WO2005041965A1 (en) 2005-05-12
KR20060103323A (ko) 2006-09-28
HK1097438A1 (en) 2007-06-29
HUP0303584A2 (hu) 2005-12-28
HU0303584D0 (en) 2003-12-29
UA86782C2 (ru) 2009-05-25
AU2004285343B2 (en) 2010-05-13
DE602004016770D1 (de) 2008-11-06
US20120115908A1 (en) 2012-05-10
PL1696922T3 (pl) 2009-03-31
EP2020233A3 (en) 2009-09-30
CA2544332C (en) 2014-09-23
EP2020233A2 (en) 2009-02-04
CY1110450T1 (el) 2015-04-29
DK1696922T3 (da) 2008-12-01
ZA200604376B (en) 2009-04-29
EA011301B1 (ru) 2009-02-27
ES2314458T3 (es) 2009-03-16
ATE409038T1 (de) 2008-10-15
US8962604B2 (en) 2015-02-24
IL175334A0 (en) 2008-04-13
US20150126551A1 (en) 2015-05-07
HRP20080660T3 (en) 2009-01-31

Similar Documents

Publication Publication Date Title
HK1097438A1 (en) Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
SE0104340D0 (sv) New compounds
HUP0303128A2 (hu) O-dezmetil-venlafaxin új szukcinátsója, eljárás az előállításukra, alkalmazása és ezt tartalmazó gyógyszerkészítmény
DE60132309D1 (de) Amin-derivate zur behandlung von apoptosis
EA200600892A1 (ru) Новые хинолиновые производные
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
TW200606164A (en) New compounds
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0102440D0 (sv) New compound
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
SE9900190D0 (sv) New compounds
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
RU2005123328A (ru) Оксазолы в качестве усилителей mgiuri
EA200100156A3 (ru) Новые производные 6-сульфамоил-3-хинолилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции
EA201000118A1 (ru) Сублингвальные или трансбуккальные композиции, содержащие янтарную кислоту и предназначенные для лечения болезни альцгеймера

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent